Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beverly S Mitchell

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Plos One|July 3, 2015
Reversibility of Defective Hematopoiesis Caused by Telomere Shortening in Telomerase Knockout MiceAparna Raval, Gregory K Behbehani, Le Xuan Truong Nguyen, et al.
Human Molecular Genetics|February 26, 2004
On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosaAileen Aherne, Avril Kennan, Paul F Kenna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2005
ACCO: ASCO core curriculum outlineHyman B Muss, Jamie Von Roenn, Lloyd Earl Damon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesRobert Z Orlowski, Thomas E Stinchcombe, Beverly S Mitchell, et al.
Blood|January 1, 2005
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesRobert Z Orlowski, Peter M Voorhees, Reynaldo A Garcia, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Plos One|July 3, 2015
Reversibility of Defective Hematopoiesis Caused by Telomere Shortening in Telomerase Knockout MiceAparna Raval, Gregory K Behbehani, Le Xuan Truong Nguyen, et al.
Human Molecular Genetics|February 26, 2004
On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosaAileen Aherne, Avril Kennan, Paul F Kenna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2005
ACCO: ASCO core curriculum outlineHyman B Muss, Jamie Von Roenn, Lloyd Earl Damon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesRobert Z Orlowski, Thomas E Stinchcombe, Beverly S Mitchell, et al.
Blood|January 1, 2005
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesRobert Z Orlowski, Peter M Voorhees, Reynaldo A Garcia, et al.
Pageof 5